Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Replication competent viruses (RCVs) detection is an important component of viral vector production to ensure the safety and efficacy of viral vector production. To detect RCVs during the production of viral vectors, Creative Biogene has developed a variety of assays. These assays can effectively detect the presence of replication competent virus in the final product.
Viral vectors are widely used in gene therapy and vaccine development. During the production of viral vectors, RCVs, including rcAAV, RCL, RCR, RCA, may be generated due to homologous or non-homologous recombination between vectors and helper viruses. With the development and application of new vector systems, changes in homologous recombination among the components of the vector system have led to more complex changes in the generation mechanism and structure of RCVs. Moreover, recombination is not only limited to recombination occurring between components of vector systems, but also between vector components and cellular genomes. These RCVs pose a significant risk to patients receiving gene therapy or vaccines, leading to unintended gene expression and potentially deleterious effects. The introduction of RCVs testing ensures that the final product is free of any replication competent viral particles that could cause harm during application, ensuring the safety and efficacy of the biologic products.
In addition to improving viral vector preparation systems and reducing the risk of producing RCVs, Creative Biogene has developed reliable methods for detecting RCVs. Our quality control team performs tests for RCVs throughout the production process and at different stages, as well as for master cell banks for vector production, working cell banks, end-of-production cells, vector supernatants and vector-transduced cells cultured in vitro for more than 4 days.
Creative Biogene's quality control team has developed various assays based on the FDA's recommended methods. These methods can determine the presence or absence of RCVs. Below is an overview of the methods we offer for detecting RCVs.
Samples containing potential viruses are mixed with a cell line that allows viral replication. The co-cultures are then incubated for a period of time to allow the virus to infect the cells and multiply. After the culture period, the cultures are screened for the presence of viral replication by monitoring changes in cell morphology or by detecting the production of viral antigens or genetic material. In Creative Biogene's laboratory, we typically test samples using multiple cell lines to increase the sensitivity of the assay and to ensure that all potentially RCVs are detected.
Viral nucleic acids are amplified using specific primers and probes that target specific regions of the viral genome. The amplified DNA is then detected using fluorescence-based methods (e.g. TaqMan PCR) or gel electrophoresis.
For safety, efficacy, and quality control reasons, Creative Biogene provides safety characterization and release testing support for viral vectors used in gene therapy. Contact us to learn more about our viral aggregation assays and we will be happy to assist you.
Copyright © 2026 Creative Biogene. All rights reserved.